Abstract C42: Quantitative high-throughput efficacy profiling of hedgehog/GLI pathway antagonists in inflammatory breast cancer

Conclusion: Several agents showed efficacy in in vitro IBC cancer models demonstrating that GLI inhibitors may be a valid therapeutic approach for targeting GLI-dependent IBC cancers.Funded in part by DOD/CDMRP IDEA W81XWH-13-1-0141(BC121850) (KP Williams)[1] W.F. Anderson, C. Schairer, B.E. Chen, K.W. Hance, P.H. Levine, Epidemiology of inflammatory breast cancer (IBC). Breast disease 22 (2006) 9-23.[2] W.A. Woodward, M. Cristofanilli, Inflammatory breast cancer. Seminars in Radiation Oncology 19 (2009) 256-265.[3] K.A. Hirko, A.S. Soliman, M. Banerjee, J. Ruterbusch, J.B. Harford, R.M. Chamberlain, J.J. Graff, S.D. Merajver, K. Schwartz, Characterizing inflammatory breast cancer among Arab Americans in the California, Detroit and New Jersey Surveillance, Epidemiology and End Results (SEER) registries (1988–2008). SpringerPlus 2 (2013).[4] J.A. Schlichting, A.S. Soliman, C. Schairer, M. Banerjee, L. Rozek, D. Schottenfeld, J.B. Harford, S.D. Merajver, Association of Inflammatory and Non-Inflammatory Breast Cancer with Socioeconomic Characteristics in the Surveillance, Epidemiology, and End Results Database, 2000-2007. Cancer Epidemiol. Biomark. Prev. (2011) DOI:10.1158/1055-9965.EPI-1111-0853.[5] Z. Thomas, W. Gibson, J. Sexton, K. Aird, S. Ingram, A. Aldrich, H. Lyerly, G. Devi, K. Williams, Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. Br. J. Cancer 104 (2011) 1575-1586.[6] K.P. Williams, J.L. Allensw...
Source: Cancer Epidemiology Biomarkers and Prevention - Category: Cancer & Oncology Authors: Tags: Proteomics, Chemogenomics, and Chemoinformatics: Poster Presentations - Proffered Abstracts Source Type: research